Clinical Trials Logo
  1. Home
  2. Diabetic Retinopathy
  3. NCT04631653
  4. Details
NCT04631653 Clinical Trial

Verisee Software for Diabetic Retinopathy Screening

Diabetic Retinopathy Clinical Trial

Official title:
The Clinical Benefit of an Artificial Intelligence Software Implementation on Diabetic Retinopathy Screening

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT04631653
Other study ID # SE20294A
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date December 1, 2020
Est. completion date December 31, 2023

Study information
Verified date November 2020
Source Taichung Veterans General Hospital
Contact I-Te Lee, MD,PhD
Phone +886-4-23592525
Email itlee@vghtc.gov.tw
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators aim to improve the diagnostic accuracy and the clinical referral rate for diabetic retinopathy by using a deep learning-based software.

Description:

Diabetic retinopathy (DR) is the leading cause of blindness among working-age patients with type 2 diabetes. According to previous studies, early screening and timely treatment can reduce the risk of worsening DR and blindness. International guidelines recommend that screening for DR be performed at least once every year for patients with type 2 diabetes. The investigators will implement a validated deep learning-based software, VeriSee®, in clinics, and evaluate the benefits on diagnostic accuracy and the clinical referral rate for diabetic retinopathy after implementation of this software.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 1000
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: - Adults - Patients with diabetes - Cooperation to fundal scopic examination Exclusion Criteria: - Diabetic duration < 5 years in patients with type 1 diabetes - Pregnancy

Study Design

Related Conditions & MeSH terms

Intervention

Device:
• VeriSee®
Screening of diabetic retinopathy using a validated deep learning-based software,VeriSee®

Locations
Country Name City State
Taiwan Division of Endocrinology and Metabolism in Taichung Veterans General Hospital Taichung

Sponsors (1)
Lead Sponsor Collaborator
Taichung Veterans General Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome
Type Measure Description Time frame Safety issue
Primary diagnostic accuracy diagnostic accuracy compared to the baseline 12 months
Secondary Screening rate of diabetic retinopathy Screening rate of diabetic retinopathy in patients with diabetes 12 months
Secondary Changes in HbA1c Changes in HbA1c 3 months
Secondary Referral rate of diabetic retinopathy Successful referral rate for referrable diabetic retinopathy 12 months
See also
  Status Clinical Trial Phase
Completed NCT03660384 - Silicone Oil Versus Gas in PDR Patients Undergoing Vitrectomy N/A
Completed NCT03660345 - PPV With Internal Limiting Membrane Peeling for Treatment-Naïve DME Phase 3
Completed NCT03660371 - ILM Peeling in PDR Patients Undergoing PPV for VH N/A
Completed NCT04905459 - ARDA Software for the Detection of mtmDR
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03713268 - Intraoperative OCT Guidance of Intraocular Surgery II
Completed NCT05022615 - Comparing 3 Imaging Systems
Completed NCT00385333 - Metabolic Mapping to Measure Retinal Metabolism Phase 2
Recruiting NCT04101604 - Biomarkers of Common Eye Diseases
Completed NCT03702374 - Combined Antioxidant Therapy on Oxidative Stress, Mitochondrial Dysfunction Markers in Diabetic Retinopathy Phase 3
Completed NCT01908816 - An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. Phase 3
Completed NCT04009980 - Long-term Retinal Changes After Topical Citicoline Administration in Patients With Mild Signs of Diabetic Retinopathy in Type 1 Diabetes Mellitus. N/A
Completed NCT02924311 - Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema
Not yet recruiting NCT06257082 - Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities N/A
Not yet recruiting NCT05452993 - Screening for Diabetic Retinopathy in Pharmacies With Artificial Intelligence Enhanced Retinophotography N/A
Withdrawn NCT02812030 - Aflibercept for Retinopathy in the Real World N/A
Completed NCT02391558 - Clinical Evaluation of Noninvasive OCT Angiography Using a Zeiss OCT Prototype to Compare to Fluorescein Angiography N/A
Active, not recruiting NCT02330042 - OCT Biomarkers for Diabetic Retinopathy
Active, not recruiting NCT02353923 - OcuStem Nutritional Supplement in Diabetic Patients With Mild to Moderate Non-proliferative Retinopathy N/A
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A